Tivic Health Systems Inc
TIVC0.858USD
+0.028+3.37%
Cierre 02/06, 16:00（ET）Cotizaciones retrasadas 15 min
1.43MCap. mercado
PérdidaP/E TTM
Más Datos de Tivic Health Systems Inc Compañía
Tivic Health Systems, Inc. is a diversified therapeutics company, with complementary bioelectronic and biologic product candidates in its clinical pipeline. It harnesses the power of the immune and autonomic nervous systems to fight disease and restore health. It takes a multi-pronged approach to treating diseases caused by immune dysregulation and dysautonomia. The complement of bioelectronic and biologic medicines allows it to target disorders and disease via both neural pathways and molecular approaches. Its commercial product, ClearUP, is clinically proven to treat sinus pain and pressure. ClearUP is available through online retailers and commercial distributors. It also has worldwide exclusive license rights to the late-stage Toll-like Receptor 5 (TLR5) agonist Entolimod for the treatment of acute radiation syndrome (ARS). In addition, it has an exclusive option to license five additional indications and clinical use cases for Entolimod and its derivative, Entalasta.
Información de Tivic Health Systems Inc
Símbolo de cotizaciónTIVC
Nombre de la empresaTivic Health Systems Inc
Fecha de salida a bolsaNov 11, 2021
Director ejecutivoErnst (Jennifer)
Número de empleados7
Tipo de seguridadOrdinary Share
Fin del año fiscalNov 11
Dirección47685 Lakeview Blvd
CiudadFREMONT
Bolsa de valoresNASDAQ OMX - NASDAQ BASIC
PaísUnited States of America
Código postal94538
Teléfono18882766888
Sitio Webhttps://tivichealth.com/
Símbolo de cotizaciónTIVC
Fecha de salida a bolsaNov 11, 2021
Director ejecutivoErnst (Jennifer)
Ejecutivos de Tivic Health Systems Inc
Nombre
Nombre/Posición
Posición
Accionistas
Cambio
Ms. Jennifer Ernst
Ms. Jennifer Ernst
Chief Executive Officer, Co-Founder, Director
Chief Executive Officer, Co-Founder, Director
32.69K
+9444.00%
Ms. Sheryle J Bolton
Ms. Sheryle J Bolton
Independent Chairman of the Board
Independent Chairman of the Board
--
--
Mr. Dean Zikria
Mr. Dean Zikria
Independent Director
Independent Director
--
--
Mr. Jim Hock
Mr. Jim Hock
Investor Relations
Investor Relations
--
--
Ms. Lisa Wolf
Ms. Lisa Wolf
Chief Financial Officer
Chief Financial Officer
--
--
Ms. Christina Valauri
Ms. Christina Valauri
Independent Director
Independent Director
--
--
Mr. Michael K. Handley
Mr. Michael K. Handley
Chief Operating Officer and President of Tivic Biopharma
Chief Operating Officer and President of Tivic Biopharma
--
--
Nombre
Nombre/Posición
Posición
Accionistas
Cambio
Ms. Jennifer Ernst
Ms. Jennifer Ernst
Chief Executive Officer, Co-Founder, Director
Chief Executive Officer, Co-Founder, Director
32.69K
+9444.00%
Ms. Sheryle J Bolton
Ms. Sheryle J Bolton
Independent Chairman of the Board
Independent Chairman of the Board
--
--
Mr. Dean Zikria
Mr. Dean Zikria
Independent Director
Independent Director
--
--
Mr. Jim Hock
Mr. Jim Hock
Investor Relations
Investor Relations
--
--
Ms. Lisa Wolf
Ms. Lisa Wolf
Chief Financial Officer
Chief Financial Officer
--
--
Ms. Christina Valauri
Ms. Christina Valauri
Independent Director
Independent Director
--
--
Desglose de ingresos
La empresa aún no ha revelado los datos relevantes.
La empresa aún no ha revelado los datos relevantes.
Por negocio
Por región
La empresa aún no ha revelado los datos relevantes.
Estadísticas de accionistas
Actualizado: dom., 11 de ene
Actualizado: dom., 11 de ene
Accionistas
Tipos de accionistas
Accionistas
Accionistas
Proporción
Avenue Capital Group
4.02%
DRW Securities, LLC
2.14%
Marex Group plc
1.52%
Ernst (Jennifer)
1.29%
UBS Financial Services, Inc.
0.78%
Otro
90.25%
Accionistas
Accionistas
Proporción
Avenue Capital Group
4.02%
DRW Securities, LLC
2.14%
Marex Group plc
1.52%
Ernst (Jennifer)
1.29%
UBS Financial Services, Inc.
0.78%
Otro
90.25%
Tipos de accionistas
Accionistas
Proporción
Investment Advisor
4.51%
Investment Advisor/Hedge Fund
4.33%
Individual Investor
1.31%
Research Firm
0.06%
Otro
89.79%
Participación institucional
Actualizado: jue., 1 de ene
Actualizado: jue., 1 de ene
Periodo del informe
Número de instituciones
Acciones mantenidas
Proporción
Cambio
2025Q4
22
224.75K
8.90%
+144.85K
2025Q3
22
44.96K
2.86%
+5.91K
2025Q2
32
112.57K
10.82%
+62.79K
2025Q1
32
1.24K
0.18%
-48.58K
2024Q4
34
288.82K
2.82%
-516.93K
2024Q3
32
301.13K
4.87%
-468.33K
2024Q2
32
639.36K
10.34%
+419.46K
2024Q1
34
88.08K
6.01%
-141.85K
2023Q4
34
75.33K
5.40%
-149.34K
2023Q3
33
160.42K
18.20%
+130.18K
Ver más
Actividad de los accionistas
Nombre
Acciones mantenidas
Proporción
Cambio
Cambio %
Fecha
Avenue Capital Group
101.64K
5.76%
+101.64K
--
Sep 30, 2025
DRW Securities, LLC
53.94K
3.05%
+53.94K
--
Sep 30, 2025
Marex Group plc
38.39K
2.17%
-890.00
-2.27%
Sep 30, 2025
Ernst (Jennifer)
32.69K
1.85%
+9.44K
+40.62%
Dec 18, 2025
UBS Financial Services, Inc.
801.00
0.05%
-4.85K
-85.83%
Sep 30, 2025
Geode Capital Management, L.L.C.
5.07K
0.29%
--
--
Nov 30, 2025
The Vanguard Group, Inc.
1.94K
0.11%
--
--
Nov 30, 2025
Citi Investment Research (US)
1.43K
0.08%
+1.43K
--
Sep 30, 2025
Wolf (Lisa G)
434.00
0.02%
+434.00
--
Dec 18, 2025
SBI Securities Co., Ltd.
16.00
0%
--
--
Sep 30, 2025
Ver más
ETFs relacionados
Nombre
Proporción
Sin datos
Dividendos
Un total de
0.00
USD se ha distribuido en dividendos durante los últimos 5 años.
Fecha
Dividendos
Fecha de registro
Fecha de pago
Fecha ex-dividendo
Sin datos
División de acciones
Fecha
Fecha ex-dividendo
Tipo
Relación
Mar 05, 2025
Merger
17→1
Mar 05, 2025
Merger
17→1
Mar 05, 2025
Merger
17→1
Mar 05, 2025
Merger
17→1
Aug 22, 2023
Merger
100→1
Aug 22, 2023
Merger
100→1
Fecha
Fecha ex-dividendo
Tipo
Relación
Mar 05, 2025
Merger
17→1
Mar 05, 2025
Merger
17→1
Mar 05, 2025
Merger
17→1
Mar 05, 2025
Merger
17→1
Aug 22, 2023
Merger
100→1
Aug 22, 2023
Merger
100→1
Aug 22, 2023
Merger
100→1
Aug 22, 2023
Merger
100→1
